In summary, the novel skeleton compound cyclizing-berberine A35, which has an inhibitory mechanism on the top2α catalytic cycle different from that of other topoisomerase inhibitors [16], could strongly inhibit cancer proliferation and induce G2/M arrest, especially M-phase arrest. Here, TOP2A is linked to cancer.